Novo Nordisk's ZEUS Trial Fails Primary Endpoint in High-Risk Cardiovascular Patients
Event summary
- ZEUS phase 3 trial of ziltivekimab failed to reduce major adverse cardiovascular events (MACE) in patients with ASCVD, CKD, and inflammation (HR: 0.99).
- Trial enrolled over 6,300 participants; ziltivekimab showed expected biological effects but no clinical benefit versus placebo.
- Novo Nordisk will take a non-cash impairment charge in Q3 2026 due to the failed trial.
- Two additional cardiovascular outcomes trials (HERMES and ARTEMIS) for ziltivekimab will continue, with results expected in H1 2027.
The big picture
Novo Nordisk's ZEUS trial failure highlights the persistent challenges in translating anti-inflammatory mechanisms into tangible cardiovascular outcomes. The setback comes amid intense competition in cardiovascular disease treatment, where novel therapies targeting inflammation have shown mixed results. Despite this, Novo Nordisk remains committed to its cardiovascular portfolio, with ongoing trials offering potential upside.
What we're watching
- Pipeline Strategy
- Whether Novo Nordisk can pivot its cardiovascular research based on ZEUS trial insights.
- Financial Impact
- The magnitude of the non-cash impairment charge and its effect on 2026 financial guidance.
- Competitive Positioning
- How competitors in cardiovascular inflammation space may capitalize on this setback.
Related topics